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Toxoplasmosis is a major cause of foodborne disease, congenital complication, and
morbidity.There is an urgent need for safe and effective therapies to encounter congenital
and persisting toxoplasmosis. The hypothesis was: combination diclazuril plus atovaquone
to exert a novel therapeutic synergy to prevent toxoplasmosis syndromes.
Methods: Pregnant dams were treated with diclazuril and atovaquone monotherapy or
combination therapy and infected i.p with Toxoplasma tachyzoites.
Results: Infected dams developed severe toxoplasmosis associated syndrome with
increases in the abdominal adiposity surrounding uteri, gansterointestinal and other
internal organs and excessive weight gain. Numerous organisms along with infiltration
of inflammatory cells were detected scattered into adipose tissues. Combination therapy
(p < 0.01) and to a lesser extent diclazuril (p < 0.05) protected dams from inflammatory
fat and excess weight gains.This was consistent with pancreatitis development in infected
dams (versus normal p < 0.05) with infiltration of inflammatory cells, degeneration and
necrosis of pancreatic cells followed by the degeneration and loss of islets. Combination
and monotherapy protected dams from these inflammatory and pathological aspects of
pancreatitis. Infected dams exhibited severe colitis, and colonic tissues significantly short-
ened in length. Brush border epithelial cells were replaced with infiltration of lymphocytes,
granulocytes, and microabscess formations into cryptic microstructures. Combination
therapy synergistically preserved colonic structure and normalized pathological damages
(p < 0.001) and to a lesser degree diclazuril monotherapy protected dams from colitis
(p < 0.05) and gastrointestinal toxoplasmosis. Other complications included severe
splenitis (p < 0.001) and hepatitis (p < 0.001) which were normalized with combination
therapy.
Conclusion: Combination diclazuril plus atovaquone was safe and with a novel therapeutic
synergism protected dams and fetuses from toxoplasmosis.
Keywords: toxoplasmosis, combination, diclazuril, atovaquone, synergism, obesity,Toxoplasma, gastroenteritis
INTRODUCTION
Toxoplasmosis is a major cause of foodborne disease, hospi-
talization, and congenital complications related morbidity and
mortality (Mead et al., 1999; Scallan et al., 2011; Hoffmann et al.,
2012). Toxoplasma is categorized as class B human pathogen by
the CDC and NIH. Toxoplasmosis, a cosmopolitan syndrome,
is considered as “forgotten disease of vulnerable and poverty”
which infects the many in rural (Hotez, 2008) as well as the
urban areas. Congenital toxoplasmosis is due to transmission of
Toxoplasma organisms from infected mom to the fetus and typi-
cally associated with pregnancy immunosuppression. Congenital
Abbreviations: BSA, bovine serum albumin; CDC, center for disease control; CNS,
central nervous system; EPM, equine protozoal myeloencephalitis; FDA, Food and
Drug Administration; H&E, hematoxylin eosin; IACUC, institutional animal care
use committee; IBC, institutional biosaftey committee; IHC, immunohistochemical
staining; i.p, intraperitoneally; MEM, minimum essential medium; NIH, national
institute of health; PBS, phosphate buffer saline; S. neurona, Sarcocystis neurona;
Tox, Toxoplasma gondii.
toxoplasmosis causes severe complications in fetal and neonate
to compromise a lifelong adverse consequences (Remington et al.,
2004; Olariu et al., 2011; Kieffer and Wallon, 2013). Toxoplasma
organisms are transmitted through consumption of contami-
nated meat, milk, dairy product with cysts forms. However, the
main source of Toxoplasma infection is considered as vegeta-
bles, fruits, and water contaminated with oocysts from cat feces
in the field, while over 93 million cats are kept as pets in the
USA. These households may include immunocompetent as well as
immunosuppressed, obese and/or diabetic and pregnant individ-
uals, and at risk of developing toxoplasmosis (Esch and Petersen,
2013).
Toxoplasmosis, a global disease, and in excess of billion people
are expected to have Toxoplasma infection. Toxoplasma is asso-
ciated with anorexia or obesity as organisms alter and reside in
inflamed adipose tissues (Carter, 2013). Excessive weight gain
is reported in infected pregnant women compared with unin-
fected individuals (Kankova et al., 2010; Flegr, 2013), as well as
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in a feto-maternal toxoplasmosis model (Oz and Tobin, 2012; Oz,
2014). Toxoplasma infected animals had increased weight gain and
atrophy of myenteric neurons of the jejunum (Hermes-Uliana
et al., 2011). Obesity has become a cosmopolitan syndrome and
poorly understood pathogenesis with a potential link to toxo-
plasmosis. Other toxoplasmosis complications are gastroenteritis,
pancreatitis, diabetes, retinochoroiditis, and encephalitis.
Current available therapy for congenital toxoplasmosis is spi-
ramycin associated with pyrimethamine plus sulfadoxine com-
bined therapy, to protect fetus from Toxoplasma organism trans-
mission in actively infected moms. However, this approach
is not always effective and the treatment has fetotoxic side
effects (Habib, 2008; Berrebi et al., 2010; Cortina-Borja et al.,
2010; Julliac et al., 2010). Pyrimethamine while used is a preg-
nancy classified C drug, which may cause bone marrow sup-
pression in the mom and the newborn. In a clinical trial in
France, 24% of sera positive women treated with spiramycin
and pyrimethamine plus sulfadoxine combination delivered Tox-
oplasma infected infants (Bessieres et al., 2009). Spiramycin
monotherapy can be effective only when administered during
early stage of pregnancy and is principally a preventive measure
(Julliac et al., 2010). More than half of patients treated with spi-
ramycin retained Toxoplasma DNA in their blood and remained
infected (Habib, 2008). Fifty-five percent of patients treated with
combination of sulfadiazine + pyrimethamine plus folinic acid
therapy have adverse effects (Capobiango et al., 2014). Mean-
while, the efficacy of azithromycin, clarithromycin, atovaquone,
dapsone, and cotrimoxazole (trimethoprim-sulfamethoxazole),
has not been clinically proven (Petersen and Schmidt, 2003).
Considering the importance of complications and the world-
wide epidemic, there is an urgent need for effective and non-
toxic therapeutic modalities for congenital or persisting chronic
toxoplasmosis.
Diclazuril and its related benzeneacetonitriles have been used
in treatment and prevention of livestock and poultry coccidio-
sis (Assis et al., 2010) and S. neurona in EPM. Diclazuril is a safe
and effective compound at therapeutic dose levels (Assis et al.,
2010; Oz and Tobin, 2014). Diclazuril targets chloroplast derived
chlorophyll a-D1 complex present in Toxoplasma and other Api-
complexans and not exists in mammalians cells (Hackstein et al.,
1995).
Atovaquone is a FDA approved toxoplasmosis treatment but
not in feto-maternal toxoplasmosis (Cortina-Borja et al., 2010;
Oz and Tobin, 2012; Oz, 2014). Atovaquone is a safe and effec-
tive drug against plasmodial infections (Hudson et al., 1991),
Babesia microti, causative of human babesiosis (Hughes and Oz,
1995; Oz and Westlund, 2012) and other opportunistic disease,
Pneumocystis pneumonia (Oz et al., 1999).
Recently, the efficacy of diclazuril and atovaquone monother-
apy were reported against inflammatory and infectious aspects
of mild to moderate feto-maternal toxoplasmosis (Oz and Tobin,
2012, 2014; Oz, 2014). Therapeutic diclazuril plus atovaquone
combination have not been previously reported against coli-
tis, pancreatitis and some other inflammatory complications in
toxoplasmosis. This investigation explores the efficacy of combi-
nation therapy with diclazuril plus atovaquone to exert a novel
therapeutic synergism to protect against toxoplasmosis.
MATERIALS AND METHODS
ETHICS
This research was conducted according to the guidelines and
approved by the IBC and the Care and Use of Laboratory Animal
Care (IACUC) at University of Kentucky Medical Center.
Toxoplasma gondii PROPAGATION
Toxoplasma Type II isolates including ME-49 strain are reported
predominant in human congenital Toxoplasmosis (Ajzenberg
et al., 2002). For this investigation, Toxoplasma organisms from
PTG strain (ME-49, ATCC50841) were originally cloned and
propagated by Dr. Daniel Howe of the Maxwell H. Gluck
Equine Research Center at the University of Kentucky (Howe
et al., 1997; Oz and Tobin, 2012). Briefly, Tachyzoites were cul-
tured by serial passage in bovine turbinate cells and maintained
in MEMRS (HyClone Labs, Inc.) supplemented with 4% fetal
clone III (HyClone, Labs, Inc.), Penicillin/streptomycin/fungizone
(BioWhittaker, Inc.), and nonessential amino acids solution
(HyClone, Labs, Inc.). Upon disruption of the host cell mono-
layer, extracellular tachyzoites were harvested and purified from
host cell debris by filtration through 3.0 μm membranes. Tachy-
zoites were enumerated in a hemocytometer and suspended in PBS
to the appropriate concentrations for inoculation. All inoculations
were administered i.p. in 100 μL volume into dams within 1 h of
harvesting to ensure viability.
CONGENITAL TOXOPLASMOSIS MODEL
Day 1 programmed pregnant (9 weeks old) CD1 mice were pur-
chased from Charles River Lab Inc., Wilmington, MA, USA). Dams
were housed individually in microisolator cages in a pathogen free
environment and maintained at 22◦C with a 12: 12 h light: dark
cycle at the Maxwell H. Gluck Equine Research Center Laboratory
Animal Facility. Animals were fed irradiated rodent chow and ster-
ilized drinking water ad libitum. After 5 days acclimation, dams
were weighed and ear punched for appropriate identification. They
were assigned into 6–8 animals per group and injected i.p. with
100 μL PBS containing 0 or 600 tachyzoites with 0.5 mL insulin
syringes. Control dams received 100 μL injection with PBS alone
(Oz and Tobin, 2012). Animals were monitored daily three times
for distress, pain, physical appearance, and vaginal discharge to
detect abortion or early delivery (Oz and Tobin, 2012, 2014). The
experiment was terminated on gestation day 16 before possible
early or premature birth to study the fetal and maternal aspects of
the disease.
SPECIMENS COLLECTION
Animals were euthanatized using CO2 inhalation. Immediately
their chests were opened and blood from heart collected in
microtainers (BD Biosource, Rockville, MD, USA) for hematocrit
evaluation. Sera were separated and stored at frozen –80◦C. The
splenic weight and length were recorded. Heart, liver, and uterus
were excised and weighed. Colonic contents were removed and
colonic length and weigh data measured and flash frozen in liquid
nitrogen and stored at –80◦C for future studies. Live fetuses were
removed from uteri, counted, and weighed and their lengths mea-
sured using a digital caliper. All aspects of the investigation were
performed according to the guidelines by Institutional Biosafety
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Committee (IBC) and IACUC at University of Kentucky Medical
Center.
DICLAZURIL AND ATOVAQUONE THERAPIES
To study safety and efficacy of diclazuril plus atovaquone
against toxoplasmosis, dams were divided into groups of 18–
24. Dams received regimens, diclazuril monotherapy, atovaquone
monotherapy, diclazuril plus atovaquone combination therapy, or
sham incorporated into daily diet (Oz et al., 2007; Oz and Tobin,
2012, 2014). The control group received sham treatment (inert
talcum powder). Treatments were initiated on Day 5 of pregnancy
and continued until day 16. On day 8 of pregnancy dams on
treatments or sham control arms were further divided into three
subgroups of 6–8 animals and were injected each with PBS alone,
or PBS containing 600 tachyzoites and treatments were continued
until dams were euthanatized. Pregnant animals voluntarily con-
sumed their diets with no significant changes in their appearance,
food consumption, or weight loss/gain.
PATHOLOGICAL ASSESSMENTS
Hematoxylin eosin staining
A portion of examined tissues from each dam was placed into
cassettes and fixed with 10% neutral PBS formalin. The specimens
were dehydrated and embedded in paraffin, and tissue sections of
5 μm were stained by H&E for histopathological evaluation.
Giemsa staining
Giemsa is a delicate polychromatic stain that reveals the fine
nuclear detail of Toxoplasma organisms (Oz and Tobin, 2012).
Giemsa stain contains methylene blue azure basic (MBAB) dyes
combined with eosin acidic dyes. The deparaffinized slide sections
were stained with the polychromatic Giemsa (40 drops/50 mL
distilled water) to stain nuclei of the Toxoplasma organisms and
to permit differentiation among the cells. Then, the slides were
depreciated in 1% glacial acetic acid, dehydrated in alcohol and
xylene series, and mounted in synthetic resin on slides.
Immunohistochemical staining (IHC)
Anti-Toxoplasma antibody and IHC procedure were kindly pro-
vided by Dr. David S. Lindsay at University of West Virginal.
Briefly, paraffin-embedded sections were cut, deparaffinized with
xylene, rehydrated in alcohol baths, washed in PBS with 0.1%
BSA, quenched endogenous peroxidase activity by incubating in
3% hydrogen peroxide in methanol for 30 min, and then blocked
with rabbit serum (Dako number 1699), 30 min. The sections were
incubated with polyclonal Rh anti-Toxoplasma antibody, diluted
1: 500 for 90 min, and developed with DAB-chromogen (Dako,
Carpinteria, CA, USA) for about 5 min until signal developed
and subsequently counterstained with hematoxylin then ammo-
nia treated dehydrate stepwise through alcohol, clear with xylene
(Oz and Tobin, 2012, 2014).
COLONIC TISSUES PREPARATION AND EVALUATION
Colonic tissues were flushed with PBS (pH 7.2) and a portion
from proximal and distal colonic tissue was fixed in 10% neutral
formalin for histological examinations. The remainder was flash-
frozen in liquid nitrogen and stored at –80◦C. The formalin fixed
sections were processed and stained with H&E and slides evaluated
by Ziess light microscopy. The severity of colitis as assessed with
a histological semiquantitative grading score and performed in
a blinded fashion. The scores were based on histopathological
features with a numeric value (0: normal to 4: severe) assigned
according to the tissue involvement that corresponded to either of
the following criteria (Oz et al., 2007, 2010, 2013).
(Grade 0)—no detectable lesions, no inflammatory cells, and
normal mucosal appearance.
(Grade 1)—focal inflammatory infiltrate in the mucosa.
(Grade 2)—mild multifocal inflammation with moderate
expansion of the mucosa.
(Grade 3)—moderate multifocal inflammation with moderate
expansion of the mucosa.
(Grade 4)—severe diffuse inflammation with crypt epithelium
disruption and ulceration.
ADIPOSITY TISSUE PREPARATION AND STAINING
Portions of the abdominal adipose tissue from each dam were
removed, placed in a cassette and fixed in the 10% buffered for-
malin and processed for histophathological slides staining with
Giemsa, IHC, and H&E to study the structure and possible
organisms.
HEPATIC TISSUE PREPARATION AND STAINING
A portion of the right lobe from liver tissues of each dam was
placed in cassette and fixed with 10% neutral PBS formalin. The
specimens were dehydrated and embedded in paraffin, and tissue
sections of 5 μm were stained by H&E. Each slide was evaluated
under Ziess light microscopy. Hepatic lesions were graded on a
scale of 0–4 + based on degeneration, inflammation, and necrosis
(Oz et al., 2006, 2011) as follows.
(Grade 0)—no detectable lesions, no degeneration, infiltration
of inflammatory cells, and normal tissue appearance.
(Grade 1)—focal infiltration of inflammatory cells in the tissue
and hepatocytes degeneration.
(Grade 2)—mild multifocal infiltration of inflammatory cells,
and hepatocytes degeneration.
(Grade 3)—moderate multifocal infiltration of inflammatory
cells and hepatocytes degeneration.
(Grade 4)—severe diffuse infiltration of inflammatory cells and
necrosis.
PAIN RELATED BEHAVIORAL TEST
Assessment of Pain Related Mechanical Allodynia by Test-
ing Abdominal Withdrawal Threshold. Abdominal withdrawal
responses to mechanical stimuli were quantified with von Frey
monofilaments (Semmes-Weinstein Anesthesiometer Kit) accord-
ing to our previous publications with some modification (Oz and
Tobin, 2012, 2014). Dams were placed into plastic enclosures on
the custom-made screen meshed platform. The monofilament
range used for this study included five different intensities cor-
responding to (hair diameter) gram force [(4.08) 1.0 g; (3.61)
0.4 g; (3.22) 0.166 g; (2.83) 0.07; (2.36) 0.02 g forces]. Testing for
mechanical stimulation was performed on the first and the last
days of treatment. A single trial consisted of five applications of
the each filament used once every 6 s to allow dam to cease any
response and return to an inactive position. Mean values of the
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percentage of responses of the abdominal withdrawal to each fil-
ament (mean withdrawal/5 × 100) were used as % scores for this
study. This behavioral test reflected basal level for reflex score and
any possible sensory changes observed in the treated mice. A total
of four dams were tested per each group.
STATISTICAL ANALYSIS
Results are expressed as mean ± SEM unless otherwise stated. Data
were evaluated with ANOVA followed by appropriate post hoc test
(Tukey compared all pairs) using GraphPad Instat version 3 for
Windows (Graph-Pad Software, San Diego, CA, USA). Statistical
significance was set at p < 0.05.
RESULTS
In the preliminary trial, groups of naïve dams were treated with
diclazuril monotherapy, atovaquone monotherapy, diclazuril plus
atovaquone combination therapy, or inert talcum sham treat-
ment. Dams consumed medicated diets with no detectable side
effects such as changes in physical appearance, appetite, food
consumption, and the rate of weight gain or fetotoxicity and
abortion.
TOXOPLASMOSIS AND INFLAMMATORY ADIPOSITY
For the next investigation, groups of dams were treated with
(a) diclazuril monotherapy, (b) atovaquone monotherapy (c)
diclazuril plus atovaquone combination therapy, or (d) received
sham treatment. Then each group was further subdivided and
injected with sham, or a dose of 600 tachyzoites. Infected
dams developed Toxoplasma infection (600 tachyzoites) versus
uninfected normal controls received sham (PBS) injection. The
infected-sham treated dams showed a progressive severe tox-
oplasmosis complications including anemia, hydrothorax, and
ascities (p < 0.05). Combination therapy with diclazuril plus
atovaquone and diclazuril monotherapy protected dams from ane-
mia, hydrothorax, and ascites (Figure 1A). Normal-sham injected
and sham-treated controls (control) gained body weight dur-
ing pregnancy compared with excessive pathological weight gain
due to accumulation of inflammatory adiposity in Toxoplasma-
infected (Tox) sham treated dams (p < 0.001). Combination
therapy with diclazuril plus atovaquone synergistically protected
dams (p < 0.01) and to a lesser extent diclazuril monotherapy
(p < 0.05) prevented pathological accumulation of adipose tissues
and excess weight gain. In contrast, atovaquone monotherapy
had no significant effect on the weight gain and accumulated
adiposity (Figure 1B). Massive inflammatory adipose depot was
detected in the abdominal cavity surrounding uteri and gas-
trointestinal and kidneys. The adipose tissues were shown to
harbor numerous inflammatory cells in H&E stainings as well as
Toxoplasma organisms as confirmed with Giemsa and IHC stain-
ings (Figure 2A). Organisms were not detectable in dams with
combination therapy.
Toxoplasma INDUCED SPLENITIS
Splenic tissues enlarged significantly and increased in weight and
length in infected-sham treated dams. Enlarged splenic tissues
from Toxoplasma infected dams showed significant infiltration of
epithelioid cells and multinucleated giant cells with loss of ger-
minal structure and caused a severe splenomegaly. Toxoplasma
organisms were detected in IHC staining. Combination therapy
diclazuril plus atovaquone synergistically prevented dams from
severe splenitis and tissue damages (p < 0.001), Figure 2B, Table 1.
Toxoplasma INDUCED COLITIS
Colonic tissues from infected-sham treated dams were signifi-
cantly shortened in length (10.4 ±0.2 vs. infected 8.7 ±0.6 cm,
p < 0.001) but decreased in weight (p < 0.01), presumably
through the mechanism of sloughing off of the brush boarder
due to infection (Figure 3A). Colonic pathology manifested
with shortening of crypts with numerous microabscess forma-
tions in the cryptic structures and infiltration of inflammatory
FIGURE 1 | (A) Toxoplasma infection caused significant anemia in sham
treated dams (Tox). Combination diclazuril plus atovaquone therapy
(Dic + Atov) and diclazuril monotherapy (Dic) protected dams but
atovaquone (Atov) monotherapy had no effect. (B) Body weight gain
during pregnancy in normal sham controls (Control) compared with
excess pathological weight due to accumulation of inflammatory fat in
Toxoplasma infected (Tox) sham treated dams (p < 0.001).
Combination therapy with diclazuril plus atovaquone synergistically
protected dams (p < 0.01) and to a lesser extent diclazuril
monotherapy (p < 0.05) prevented pathological fat accumulation and
excess weight gain. Atovaquone monotherapy had no significant effect
(n = 6–8/group).
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FIGURE 2 | (A) Demonstrates inflammatory fat depot located in abdominal
cavity and harboring numerous organisms. IHC stainedToxoplasma organisms
(dark brown). (n = 6 group). (B) Spelenic weight distribution in Toxoplasma
(Tox) infected (p < 0.001) compared to diclazuril (Dic) monotherapy (p < 0.01),
atovaquone (Atov), synergistic effect of diclazuirl plus atovaquone (Dic + Atov)
combination therapy (p < 0.001) and normal sham controls (Co). (n = 6/group).
Table 1 | Efficacy of diclazuril and atovaquone monotherapy or combination treatment on toxoplasmosis.
Tissues Control Tox Tox + Dic Tox + Atov Tox + Dic + Atov
Fetal weight 700 ± 40 530 ± 14c 650 ± 25b 710 ± 25 720 ± 20
Splenic length (mg) 2.28 ± 013 3.22 ± 0.2c 2.8 ± 0.18 3 ± 0.1a 2.3 ± 0.13b
Pain score*(%) 20 ± 6 43 ± 3b 40 ± 4b 25 ± 2.9 25 ± 2.8
Tissues from normal sham treated and PBS containing no tachyzoites injected controls (Control), infected-dams with Toxoplasma tachyzoites and treated with sham
(Tox), compared with infected dams from diclazuril monotherapy (Tox + Dic), Atovaquone monotherapy (Tox + Atov), or combination diclazuril plus Atovaquone
(Tox + Dic + Atov) therapy. Dams were monitored daily three times until day 16 of pregnancy before termination. Number 6–8/each group.
*Percent abdominal pain related behavioral response to von Frey stimuli with 0.166 GM force. Abdominal hypersensitivity significantly increased in infected dams
(Tox). Combination therapy (Atov + Dic + Atov) and atovaquone monotherapy (Tox + Atov) similarly normalized pain induced behavioral modification in dams, but
diclazuril monotherapy (Tox + Dic) had no effect. ap < 0.05; bp < 0.01; c p < 0.001.
cells, including lymphocytes, with scattered neutrophils detected
in the mucosal architecture. Combination therapy synergis-
tically prevented pathologic changes (p < 0.001) and to a
lesser extent diclazuril monotherapy (p < 0.05) preserved the
colonic length and weight and the integrity of the microstruc-
ture against inflammatory response (Figure 3B). In contrast,
atovaquone monotherapy had no significant protective effect
on colonic inflammation and necrotic/atrophic responses to the
infection.
Toxoplasma INDUCED HEPATITIS
Hepatic structures of infected-sham treated dams enlarged
twofold and increased in weight due to a substantial inflam-
matory response to the organisms (p < 0.001) Figure 4A.
Pathological investigation demonstrated severe hepatitis with
infiltration of inflammatory cells, multinucleated dysplastic hep-
atocytes, giant cell transformation, stellate cells activation and
hepatic cells necrosis (pathological mean score of 3.5 from 4
most severe) Figure 4B. Combination therapy with diclazuril
plus atovaquone exerted unique synergism and preserved hep-
atic appearance, weight and microstructure (p < 0.001) and to a
lesser degree, diclazuril monotherapy (P < 0.01) and atovaquone
monotherapy (p < 0.05) prevented Toxoplasma induced hepati-
tis (Figures 4A,B). Overall, these effects of combination therapy
present an striking synergy between two structurally distinct com-
pounds in protecting architecture from exaggerated inflammatory
reaction.
Toxoplasma INDUCED PANCREATITIS
This was consistent with moderate to severe Toxoplasma induced
pancreatitis in infected dams (p < 0.05) with infiltration of
inflammatory cells, vacuolization, degeneration, and necrosis of
pancreatic cells followed by the degeneration and loss of beta cells
and islets (Figure 5A). Combination therapy with diclazuril plus
atovaquone therapy and monotherapy protected dams from these
inflammatory and pathological aspects of pancreatitis (Figure 5B)
and gastrointestinal toxoplasmosis.
CONGENITAL TOXOPLASMOSIS
Infected dams had nested smaller fetuses (p < 0.001) and spo-
radic preterm labor or stillbirth. Combination therapy diclazuril
plus atovaquone as well as monotherapy with atovaquone sim-
ilarly and to a lesser extent diclazuril monotherapy (p < 0.01)
protected nested fetuses from retardation and demise (Table 1). In
addition, uteri considerably augmented owing to accumulation of
inflammatory fat, influx of inflammatory cells in infected-sham
treated dams and Toxoplasma organisms were detected in Giemsa
stained and IHC slides (not shown). Combination therapy with
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FIGURE 3 | (A) Colonic section stained with H&E from Toxoplasma
infected sham treated dam (Tox) developed severe colitis with
destruction of brush border, and loss of colonic epithelial cells,
microabscess formation (open arrow) and infiltration of inflammatory
cells into mucosa (n = 6 /group). (B) Colonic length shortened due to
infiltration of inflammatory cells, and microabscess formation in infected
sham treated dams (p < 0.001). Combination therapy with diclazuril plus
atovaquone (Dic + Atov) preserved colonic structure and to a lesser
extent Diclazuril (Dic) monotherapy improved the colitis (p < 0.01).
(n = 6–8/group).
FIGURE 4 | (A) Hepatic weight distribution in Toxoplasma (Tox) infected
(p < 0.001) compared to diclazuril (Dic) monotherapy (p < 0.01),
atovaquone (Atov) monotherapy and combined diclazuirl plus
atovaquone (Dic + Atov) therapy (p < 0.001) and normal sham
controls (Co). (B) Hepatic pathological score distribution in Toxoplasma
(Tox) infected dams (p < 0.001) compared to diclazuril (Dic)
monotherapy (p < 0.01), atovaquone (Atov) monotherapy (p < 0.05),
combination diclazuirl plus atovaquone (Dic + Atov) therapy
(p < 0.001) and normal sham controls (Co). Pathological slides were
stained with H&E. (n = 6–8/group).
diclazuril plus atovaquone improved the infectious inflammatory
response and edema but with no significant changes in the uteri
weight, presumably due to the increased number of healthy fetuses
(not shown).
TOXOPLASMOSIS AND ABDOMINAL HYPERSENSITIVITY
Finally, pain related abdominal hypersensitivity significantly ele-
vated in Toxoplasma infected-sham treated dams manifested with
severe abdominal withdrawal and excess grooming in compar-
ison to normal sham control dams (p < 0.05). Combination
diclazuril plus atovaquone therapy and atovaquone monother-
apy preserved the normal abdominal response to von Frey
stimuli (Table 1). However, diclazuril monotherapy had no
significant effect on the dams’ response to the mechanical
stimuli.
DISCUSSION
Toxoplasma is a leading cause of foodborne diseases, congeni-
tal complications, morbidity and mortality. Yet, toxoplasmosis
is an underestimated syndrome and usually detected in autopsy
or remains undetected due to the non-specific symptoms and
lack of clinical awareness of healthcare individuals (Munir et al.,
2000). Toxoplasma organisms are transmitted through consump-
tion of undercooked meat, milk and dairy product contaminated
with cysts forms. However, the predominant source of Toxoplasma
infection is considered as vegetables, and fruits contaminated with
oocysts from the cat feces in the field (Oz, 2014). In addition,
contaminated water is reported as a major source for infection
during pregnancy in rural area (Andiappan et al., 2014). Consid-
ering high number of cats (>93 million) residing in households in
the USA, immunocompromised individuals, and expecting moms,
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FIGURE 5 | Pancreatic section from Toxoplasma infected and treated
dams stained with H&E. (A) Pancreatitis: demonstrates loss of
microstructure, degeneration, and necrosis of pancreatic cells,
degeneration and loss of islets, replaced with infiltration of inflammatory
cells. (B) Combination diclazuirl plus atovaquone (Dic + Atov) therapy
protected pancreatic architecture against inflammatory and infectious
response, and preserved panc and beta cells, and islet’s microstructure.
(n = 6–8/group).
as well as the increasing obese and/or diabetic population are
at a high risk of developing toxoplasmosis (Esch and Petersen,
2013). Therefore, awareness of healthcare communities as well as
individuals is necessary to contain stray cats, and prevent pets
from infection in order to protect the owners from imminent
complications.
Toxoplasmosis is a“forgotten disease of vulnerable and poverty”
which infects the many in rural (Hotez, 2008) as well as urban
area. While, poverty persists, obesity has become a cosmopolitan
complication with undetermined pathogenesis. This investigation
reports accumulation of excessive infectious and inflammatory
adiposity and pathological weight gain in Toxoplasma infected
dams. Toxoplasma association with obesity was supported in a
clinical trial with 999 psychiatric healthy normal subjects with
exclusion of those with personality and serious mental disor-
ders which have strong association with toxoplasmosis as well
as obesity (Reeves et al., 2013). Individuals with positive anti-
Toxoplasma antibodies had twice the odds to be obese compared
to seronegative individuals. Further, obese individuals had sig-
nificantly higher anti-Toxoplasma IgG titers compared to those
who were not obese (Reeves et al., 2013). In contrast, no rela-
tion with obesity and anti-Toxoplasma IgG titers was reported
in a trial with confounding factor of excluding individuals over
45 years of age when subjects mostly are prone to develop tox-
oplasmosis reactivation and obesity (Thjodleifsson et al., 2008).
Toxoplasma may alter weight gain by reducing muscle lipopro-
tein lipase and modulating tissue lipoprotein lipase activity during
chronic infection to promote triglyceride distribution in adipose
tissue (Picard et al., 2002). From 1227 Mexican Americans tested
for anti-Toxoplasma, 110 (9%) were found seropositive. In fact,
this population commonly suffers from high rates of chronic
inflammatory diseases, obesity and type-2 diabetes, further sug-
gesting a correlation between toxoplasmosis and these chronic
complications (Rubicz et al., 2011).
Toxoplasmosis may manifest with clinical symptoms of acute
or recurrent abdominal pain and pancreatitis (Parenti et al.,
1996). Chronic progressive pancreatitis may be associated with
fat necrosis, obstruction of bile duct, focal hepatic necro-
sis, elevated amylase and lipase serum values, and abdominal
fat. Similarly, in this study infected dams developed increased
abdominal inflammatory pain related modifications and severe
pancreatitis and hepatitis. There is an association of Toxoplasma
infection with liver cirrhosis. While, severity of toxoplasmosis
complications depend on the immune status of the patient and
the strain. Acute Toxoplasma infection in mice with RH strain
reveal a significant correlation between the increased number
of hepatic stellate cells and the amount of Toxoplasma anti-
gens, representing an active role for hepatic stellate cells in
the pathogenesis of Toxoplasma-induced hepatitis (Atmaca et al.,
2013). Moreover, the prevalence of anti-Toxoplasma IgG is signif-
icantly higher among the primary biliary cirrhosis patients (71%)
compared with controls without cirrhosis (40%, p < 0.0001),
whereas the infection burden is rare in healthy subjects (20%
vs. 3%, respectively, p < 0.0001). It is predicted that Tox-
oplasma to increase the risk of primary biliary cirrhosis in
patients (Shapira et al., 2012). Since, latent infection is fairly com-
mon, and once infected organisms reside for the lifelong; the
Toxoplasma interventions with safe and effective regimens will
have a great impact on health related concerns in vulnerable
individuals.
Available treatments for toxoplasmosis, sulfasalazine, pyrime-
thamine, sulfadiazine, and spiramycin, have major side effects
and not always effective. Seroconvert pregnant women are treated
with spiramycin to reduce the risk of fetal placental transmis-
sion. However, spiramycin treated patients retain Toxoplasma
DNA in peripheral blood and remain infected (Habib, 2008).
In addition, spiramycin is effective only in early pregnancy and
not after organisms penetrate the placenta and fetus (Julliac et al.,
2010). In a 20 year prospective trial of infected moms treated with
spiramycin alone or combined with pyrimethamine-sulfadoxine,
17% of newborns had established congenital toxoplasmosis and
26% developed chorioretinitis after birth (Berrebi et al., 2010). In
another study the transmission rates of toxoplasmosis were 7% in
the first, 24% second, and 59% in third trimesters, respectively,
for infected mothers treated with combination spiramycin and
pyrimethamine-sulfadoxine (Bessieres et al., 2009).
Because of these shortfalls, there is urgent need for more
effective therapeutic modalities with no toxicity to encounter
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congenital as well as recurrent toxoplasmosis. In this investigation
combination of diclazuril plus atovaquone therapy synergistically
protected dams and fetuses from severe complications of toxoplas-
mosis including gastrointestinal and the inflammatory adiposity
accumulation.
Atovaquone (hydroxy-1,4-naphthoquinone) an standard of
therapy against acute toxoplasmosis is not approved for congenital
infection. Atovaquone suppresses mild gastrointestinal toxoplas-
mosis in pregnancy model (Oz and Tobin, 2012; Oz, 2014).
However, atovaquone monotherapy is not effective against severe
complications of colitis, hepatitis and splenits and inflammatory
fatty deposits as shown here.
Additionally, diclazuril (4-chlorophenyl [2,6-dichloro-4-(4,5-
dihydro-3H-3,5-dioxo-1,2,4-triazin-2-yl)pheny l] acetonitrile) is
used in livestock to prevent coccidiosis and equine infection with
S. neurona. Diclazuril is orally absorbed with steady-state con-
centrations in plasma and cerebrospinal fluid (CSF) to inhibit
the proliferation of 95% of the organisms (Assis et al., 2010;
Oz, 2014; Oz and Tobin, 2014). Dicalzuril exclusively binds and
affects Toxoplasma organelle for photosynthetic reaction center
(protochlorophyllide) containing a trace of chlorophyll (Hack-
stein et al., 1995). This herbicidal-binding site for diclazuril is
highly specific for Toxoplasma and other Apicomplexans, pro-
viding an exceptional chemotherapeutic sensitivity. Therefore,
diclazuril binds the chloroplast epitopes and interacts with the
D1 protein, with no intervention with the mammalian cells. In
addition, diclazuril downregulates expression of serine/threonine
protein phosphatase and causes apoptosis of Eimeria tenella
merozoites (Zhou et al., 2013). Serine/threonine protein phos-
phatase (EtRACK) has 98% homology with Toxoplasma with
a predicted mechanism of action for diclazuril efficacy against
toxoplasmosis. Diclazuril dose dependently protects against mod-
erate feto-maternal gastrointestinal complications in model (Oz,
2014; Oz and Tobin, 2014). Yet, combination diclazuril plus
atovaquone therapy has superior synergic effects against toxoplas-
mosis in comparison to diclazuril and atovaquone monotherapy.
As such, combination therapy with a promising safety and effi-
cacy proven in the most vulnerable group during “fetal maternal”
stages can be applicable as a preventive measure in the endemic
areas specifically in pregnancy as well as in pets. It is antic-
ipated that the novel combination diclazuril plus atovaquone
therapy to be as effective in maternal congenital as well as
acute and chronic persistence CNS and ocular toxoplasmosis in
patients.
CONCLUSION
Diclazuril plus atovaquone combination was safe with a novel
therapeutic synergism protected dams from inflammatory and
infectious colitis, pancreatitis, obesity and other pathological
complications as well as preserved the fetuses against congenital
toxoplasmosis. The future trials will prove the anti-toxoplasmonsis
properties of diclazuril plus atovaquone combination in acute or
chronic ocular, CNS and congenital toxoplasmosis in patients.
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